Upgrade to SI Premium - Free Trial

Ascendis Pharma (ASND)

218.84 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Analysts see a buying opportunity in this pharma stock June 3, 2026 4:30 AM - StreetInsider Form 4 Ascendis Pharma A/S For: Jun 02 Filed by: SMITH SCOTT THOMAS June 2, 2026 4:25 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 29 Filed by: BIENAIME JEAN JACQUES June 1, 2026 4:11 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 29 Filed by: SMITH SCOTT THOMAS June 1, 2026 4:11 PM - SEC Filing Form 3/A Ascendis Pharma A/S For: Mar 18 Filed by: SMITH SCOTT THOMAS June 1, 2026 4:10 PM - SEC Filing JPMorgan says large-cap biotech is back as profits and pipelines fuel upside May 28, 2026 4:07 PM - StreetInsider Form 4 Ascendis Pharma A/S For: May 26 Filed by: BIENAIME JEAN JACQUES May 27, 2026 4:06 PM - SEC Filing Form SD Ascendis Pharma A/S May 22, 2026 4:03 PM - SEC Filing JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms May 20, 2026 3:10 PM - StreetInsider JPMorgan Reinstates Ascendis Pharma (ASND) at Overweight May 20, 2026 4:30 AM - StreetInsider Citi Starts Ascendis Pharma (ASND) at Buy May 18, 2026 4:14 PM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC May 15, 2026 12:36 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $329 at Evercore ISI May 15, 2026 7:15 AM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: Capital International Investors May 14, 2026 12:53 PM - SEC Filing Form 6-K Ascendis Pharma A/S For: May 13 May 13, 2026 4:05 PM - SEC Filing Form 4 Ascendis Pharma A/S For: May 11 Filed by: JENSEN FLEMMING STEEN May 12, 2026 4:09 PM - SEC Filing Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN May 11, 2026 3:37 PM - SEC Filing Ascendis Pharma (ASND) PT Raised to $345 at Barclays May 11, 2026 3:26 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $326 at Wells Fargo May 8, 2026 7:29 AM - StreetInsider Ascendis Pharma (ASND) PT Lowered to $328 at Stifel May 7, 2026 12:53 PM - StreetInsider Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc. May 7, 2026 11:03 AM - SEC Filing Form SCHEDULE 13G Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc. May 7, 2026 10:32 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: May 07 May 7, 2026 7:50 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Mar 31 May 7, 2026 7:46 AM - SEC Filing Ascendis Pharma (ASND) Tops Q1 EPS by 9c May 7, 2026 7:40 AM - StreetInsider Ascendis Pharma Reports First Quarter 2026 Financial Results May 7, 2026 7:30 AM - Globe NewsWire Ascendis reports sustained growth in achondroplasia trial subgroup May 6, 2026 4:01 PM - StreetInsider New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years May 6, 2026 4:01 PM - Globe NewsWire Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: FMR LLC May 6, 2026 11:01 AM - SEC Filing Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 April 30, 2026 4:01 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Apr 21 April 21, 2026 5:16 PM - SEC Filing Ascendis Pharma calls for redemption of $575 million convertible notes April 21, 2026 4:31 PM - StreetInsider Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 April 21, 2026 4:31 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Apr 21 April 21, 2026 9:24 AM - SEC Filing Form 8-A12B/A Ascendis Pharma A/S April 20, 2026 9:01 AM - SEC Filing Form 6-K Ascendis Pharma A/S For: Apr 20 April 20, 2026 8:02 AM - SEC Filing Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq April 20, 2026 8:00 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Apr 15 April 16, 2026 6:02 AM - SEC Filing Ascendis Pharma (ASND) PT Raised to $292 at BofA Securities April 15, 2026 4:36 PM - StreetInsider Liberty All-Star® Growth Fund, Inc. March 2026 Monthly Update April 14, 2026 5:29 PM - BizWire Form 6-K Ascendis Pharma A/S For: Apr 08 April 8, 2026 4:03 PM - SEC Filing Form 6-K Ascendis Pharma A/S For: Apr 08 April 8, 2026 4:02 PM - SEC Filing Ascendis Pharma to List Ordinary Shares Directly on Nasdaq April 8, 2026 12:00 PM - Globe NewsWire Ascendis shows combination therapy benefits in achondroplasia trial April 8, 2026 8:02 AM - StreetInsider New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia April 8, 2026 8:01 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Apr 06 April 7, 2026 12:36 PM - SEC Filing Ascendis launches YUVIWEL for achondroplasia in US market April 6, 2026 4:01 PM - StreetInsider Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States April 6, 2026 4:01 PM - Globe NewsWire Form 3 Ascendis Pharma A/S For: Mar 23 Filed by: BIENAIME JEAN JACQUES April 1, 2026 4:10 PM - SEC Filing Ascendis Pharma (ASND) Reiterated at Overweight by Cantor Fitzgerald After Model Update April 1, 2026 7:03 AM - StreetInsider Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress March 31, 2026 8:01 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Mar 30 March 30, 2026 5:30 PM - SEC Filing Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization March 25, 2026 4:53 PM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Mar 24 March 24, 2026 4:05 PM - SEC Filing Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives March 19, 2026 8:01 AM - PR NewsWire Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Fairey William March 18, 2026 6:15 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: IMANI SIHAM March 18, 2026 6:14 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SMITH SCOTT THOMAS March 18, 2026 6:14 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: JENSEN MICHAEL WOLFF March 18, 2026 6:13 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Bodenhoff Mads March 18, 2026 6:12 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG March 18, 2026 6:12 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Morrison Lisa March 18, 2026 6:11 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: HOLTUG LARS March 18, 2026 6:10 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SPROGOE KENNETT March 18, 2026 6:10 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Wu Jay Donovan March 18, 2026 6:06 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: MIKKELSEN JAN MOLLER March 18, 2026 6:06 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: JENSEN FLEMMING STEEN March 18, 2026 6:03 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Cha Albert March 18, 2026 6:03 PM - SEC Filing Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Shu Aimee March 18, 2026 6:01 PM - SEC Filing RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns' March 18, 2026 9:21 AM - StreetInsider Form 6-K Ascendis Pharma A/S For: Mar 17 March 17, 2026 4:06 PM - SEC Filing Ascendis Pharma reports positive Turner syndrome trial results for TransCon hGH March 17, 2026 8:32 AM - StreetInsider New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 March 17, 2026 8:31 AM - Globe NewsWire Form 6-K Ascendis Pharma A/S For: Mar 16 March 16, 2026 4:06 PM - SEC Filing New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 March 16, 2026 8:00 AM - Globe NewsWire Liberty All-Star® Growth Fund, Inc. February 2026 Monthly Update March 13, 2026 4:08 PM - BizWire Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy March 12, 2026 8:49 AM - PR NewsWire Form 6-K Ascendis Pharma A/S For: Mar 11 March 11, 2026 4:07 PM - SEC Filing Form 144 Ascendis Pharma A/S Filed by: SINGEL STINA March 9, 2026 5:30 PM - SEC Filing Full Article List